Madrigal Pharmaceuticals, Inc.
MDGLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMadrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. At a $12.34B market cap, Madrigal Pharmaceuticals, Inc. ranks as a large-cap company within healthcare. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Market Cap
$12.34B
Beta
-0.99
P/E (TTM)
—
P/E (Fwd)
55.50
EPS (TTM)
$-14.01
EPS (Fwd)
$9.63
ROE
-53.3%
ROA
-17.8%
Cash
$838.8M
Total Debt
$347.8M
Free CF
-$80.5M
52W Change
25.8%
Annual Financials
Cash vs Debt
Where MDGL stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, MDGL finished 6.42% above its 150-day moving average ($501.57) and 3.62% above its 200-day moving average ($515.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDGL overbought or oversold?
At the August 31, 2026 close, MDGL's RSI(14) was 56.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $838.8M in cash and $347.8M in debt, MDGL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$80.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -53.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
MDGL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, MDGL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MDGL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.